NCT03015701

S9005 Mifepristone in Meningioma

Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 193 (actual)
• Sponsor: SWOG Cancer Research Network · Network
• Sex: All
• Age: 18 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

To compare daily oral mifepristone vs placebo with respect to time to treatment failure in patients with unresectable meningioma.

Detailed description

To compare daily oral mifepristone vs placebo with respect to time to treatment failure in patients with unresectable meningioma and to address issues of safety in this patient population.

Conditions

• Meningioma

Interventions

Type	Name	Description
DRUG	Mifepristone	a 19 norsteroid with anti-progesterone and anti glucocorticoid activity which competitively inhibits binding of the hormone to its receptor
OTHER	Placebo	placebo matching mifepristone

Timeline

• Start date: 1992-08-01
• Primary completion: 2001-10-01
• Completion: 2012-11-01
• First posted: 2017-01-10
• Last updated: 2019-12-23